| The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern R Abdelnabi, CS Foo, D Jochmans, L Vangeel, S De Jonghe, ... Nature Communications 13 (1), 719, 2022 | 108 | 2022 |
| Asymmetric dihydroxylation of enynes KS Jeong, P Sjö, KB Sharpless Tetrahedron letters 33 (27), 3833-3836, 1992 | 83 | 1992 |
| Explanation for main features of structure–genotoxicity relationships of aromatic amines by theoretical studies of their activation pathways in CYP1A2 I Shamovsky, L Ripa, L Borjesson, C Mee, B Nordén, P Hansen, ... Journal of the American Chemical Society 133 (40), 16168-16185, 2011 | 75 | 2011 |
| Open Science Discovery of Potent Non-Covalent SARS-CoV-2 Main Protease Inhibitors COVID Moonshot Consortium, H Achdout, A Aimon, DS Alonzi, R Arbon, ... BioRxiv, 2020.10. 29.339317, 2020 | 36 | 2020 |
| Neutrophil elastase inhibitors: recent advances in the development of mechanism-based and nonelectrophilic inhibitors P Sjö Future Medicinal Chemistry 4 (5), 651-660, 2012 | 36 | 2012 |
| Toward the Design of Molecular Chameleons: Flexible Shielding of an Amide Bond Enhances Macrocycle Cell Permeability M Tyagi, V Poongavanam, M Lindhagen, A Pettersen, P Sjö, S Schiesser, ... Organic Letters 20 (18), 5737-5742, 2018 | 35 | 2018 |
| Theoretical studies of chemical reactivity of metabolically activated forms of aromatic amines toward DNA I Shamovsky, L Ripa, N Blomberg, LA Eriksson, P Hansen, C Mee, ... Chemical Research in Toxicology 25 (10), 2236-2252, 2012 | 35 | 2012 |
| Pharmaceutically active compounds H Bergstrand, K Karabelas, P Sjö US Patent 6,271,231, 2001 | 35 | 2001 |
| Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease GD Noske, E de Souza Silva, MO de Godoy, I Dolci, RS Fernandes, ... Journal of Biological Chemistry 299 (3), 2023 | 33 | 2023 |
| Pyridopyrimidine Derivatives and Their Use as PDE4 Inhibitors R Austin, RV Bonnert, SF Hunt, G Nikitidis, HJ Sanganee, PO Sjo, ... US Patent App. 12/293,480, 2009 | 31 | 2009 |
| Mining natural products for macrocycles to drug difficult targets F Begnini, V Poongavanam, B Over, M Castaldo, S Geschwindner, ... Journal of Medicinal Chemistry 64 (2), 1054-1072, 2020 | 30 | 2020 |
| Protein kinase inhibitors K Karabelas, M Lepistö, P Sjö US Patent 6,346,625, 2002 | 29 | 2002 |
| Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors ML Boby, D Fearon, M Ferla, M Filep, L Koekemoer, MC Robinson, ... Science 382 (6671), eabo7201, 2023 | 21 | 2023 |
| Theoretical studies of the mechanism of N-hydroxylation of primary aromatic amines by cytochrome P450 1A2: radicaloid or anionic? L Ripa, C Mee, P Sjo, I Shamovsky Chemical Research in Toxicology 27 (2), 265-278, 2014 | 21 | 2014 |
| Toward consensus on correct interpretation of protein binding in plasma and other biological matrices for COVID‐19 therapeutic development M Boffito, DJ Back, C Flexner, P Sjö, TF Blaschke, PW Horby, D Cattaneo, ... Clinical Pharmacology & Therapeutics 110 (1), 64-68, 2021 | 20 | 2021 |
| Importance of binding site hydration and flexibility revealed when optimizing a macrocyclic inhibitor of the Keap1–Nrf2 protein–protein interaction F Begnini, S Geschwindner, P Johansson, L Wissler, RJ Lewis, ... Journal of medicinal chemistry 65 (4), 3473-3517, 2022 | 18 | 2022 |
| Pharmaceutically active compounds K Karabelas, M Lepistö, P Sjö US Patent 6,492,406, 2002 | 18 | 2002 |
| Cyclic Peptide Production Using a Macrocyclase with Enhanced Substrate Promiscuity and Relaxed Recognition Determinants CN Alexandru-Crivac, C Umeobika, N Leikoski, J Jokela, K Rickaby, P Sjö, ... Chem. Commun. 53, 10656-10659, 2017 | 17 | 2017 |
| Antiviral and anti-inflammatory activities of fluoxetine in a SARS-CoV-2 infection mouse model D Péricat, SA Leon-Icaza, M Sanchez Rico, C Mühle, I Zoicas, ... International Journal of Molecular Sciences 23 (21), 13623, 2022 | 16 | 2022 |
| Susceptibility testing of medically important parasites A Genetu Bayih, A Debnath, E Mitre, CD Huston, B Laleu, D Leroy, ... Clinical Microbiology Reviews 30 (3), 647-669, 2017 | 16 | 2017 |
Lena RipaRIA iMed, AstraZenecaVerified email at astrazeneca.com
